Informations générales (source: ClinicalTrials.gov)
NK Cell Deregulation in HBV Patients (LiNKeB)
Interventional
N/A
University Hospital, Limoges (Voir sur ClinicalTrials)
décembre 2018
mars 2024
10 mai 2025
Natural Killer (NK) cells play a large role in the innate immune response as they are
equipped to kill infected or tumor cells. They express a panel of activating and
inhibitory receptors that regulate the destruction of the target cell. Many reports have
shown that NK cell function is suppressed in CHB patients. Exhaustion occurs when
activating receptors become over stimulated leading to the loss of NK function. The
investigators hypothesize that NK cells are rendered dysfunctional/ exhausted by HBV. The
primary objective is to determined the phenotypical modifications and mechanisms
associated to NK cell dysfunction, during different phases of CHB infection, in not
treated patients.
Etablissements
| Les établissements hors Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| Limoges Hospital - 87 042 - Limoges - France | Véronique LOUSTAUD-RATTI, MD | Contact (sur clinicalTrials) | |||
Critères
Tous
Inclusion Criteria:
Patients must meet all of the following inclusion criteria to be eligible for
participation in this study:
- Male or female, age ≥18 years
- HBV infection or chronic HBV infection
- Willing and able to provide written informed consent
Healthy donors must meet all of the following inclusion criteria to be eligible for
participation in this study:
- Male or female, age between 18 and 50 years
- Willing and able to provide written informed consent
Patients must meet all of the following inclusion criteria to be eligible for
participation in this study:
- Male or female, age ≥18 years
- HBV infection or chronic HBV infection
- Willing and able to provide written informed consent
Healthy donors must meet all of the following inclusion criteria to be eligible for
participation in this study:
- Male or female, age between 18 and 50 years
- Willing and able to provide written informed consent
- Subjects who meet any of the following exclusion criteria are not to be enrolled in
this study:
- Infection with hepatitis C virus (HCV) or human immunodeficiency virus (HIV)
- Chronic liver disease of a non-HBV etiology
- Immune or cancerous disease